Now showing items 1-8 of 8

  • ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. 

    Feldinger, K; Generali, D; Kramer-Marek, G; Gijsen, M; Ng, TB; Wong, JH; Strina, C; Cappelletti, M; Andreis, D; Li, J-L; Bridges, E; Turley, H; Leek, R; Roxanis, I; Capala, J; Murphy, G; Harris, AL; Kong, A (United States, 2014-08-30)
    Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, resistance remains a challenge. We have previously shown that ADAM17 plays a key role in maintaining HER2 phosphorylation during trastuzumab ...
  • Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. 

    Leung, W-Y; Roxanis, I; Sheldon, H; Buffa, FM; Li, J-L; Harris, AL; Kong, A (United States, 2015-03-20)
    Acquired resistance to lapatinib, an inhibitor of EGFR and HER2 kinases, is common. We found that reactivation of EGFR, HER2 and HER3 occurred within 24 hours of lapatinib treatment after their initial dephosphorylation. ...
  • Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. 

    Kumar, K; Wigfield, S; Gee, HE; Devlin, CM; Singleton, D; Li, J-L; Buffa, F; Huffman, M; Sinn, AL; Silver, J; Turley, H; Leek, R; Harris, AL; Ivan, M (Germany, 2013-06)
    Inhibition of vascular endothelial growth factor increases response rates to chemotherapy and progression-free survival in glioblastoma. However, resistance invariably occurs, prompting the urgent need for identification ...
  • IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide. 

    Ramcharan, R; Aleksic, T; Kamdoum, WP; Gao, S; Pfister, SX; Tanner, J; Bridges, E; Asher, R; Watson, AJ; Margison, GP; Woodcock, M; Repapi, E; Li, J-L; Middleton, MR; Macaulay, VM (United States, 2015-11-24)
    Prior studies implicate type 1 IGF receptor (IGF-1R) in mediating chemo-resistance. Here, we investigated whether IGF-1R influences response to temozolomide (TMZ), which generates DNA adducts that are removed by ...
  • Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. 

    Canonici, A; Gijsen, M; Mullooly, M; Bennett, R; Bouguern, N; Pedersen, K; O'Brien, NA; Roxanis, I; Li, J-L; Bridge, E; Finn, R; Siamon, D; McGowan, P; Duffy, MJ; O'Donovan, N; Crown, J; Kong, A (United States, 2013-10)
    Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients. However, a significant proportion of HER2-positive patients are either inherently resistant or develop resistance to ...
  • RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. 

    Wang, S; Huang, X; Li, Y; Lao, H; Zhang, Y; Dong, H; Xu, W; Li, J-L; Li, M (United States, 2011-06)
    UNLABELLED: The activation of oncogenes and the inactivation of tumor suppressor genes by mutations or chronic hepatitis virus infections play key roles in the pathogenesis of hepatocellular carcinoma (HCC). Here we report ...
  • Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. 

    Oon, CE; Bridges, E; Sheldon, H; Sainson, RCA; Jubb, A; Turley, H; Leek, R; Buffa, F; Harris, AL; Li, J-L (United States, 2017-06-20)
    Delta-like 4 (DLL4) and Jagged1 (JAG1) are two key Notch ligands implicated in tumour angiogenesis. They were shown to have opposite effects on mouse retinal and adult regenerative angiogenesis. In tumours, both ligands ...
  • TGFβR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness. 

    Lyu, X; Fang, W; Cai, L; Zheng, H; Ye, Y; Zhang, L; Li, J; Peng, H; Cho, WCS; Wang, E; Marincola, FM; Yao, K; Cai, H; Li, J; Li, X (England, 2014-03-08)
    BACKGROUND: MiR-17-92 cluster and its paralogues have emerged as crucial regulators of many oncogenes and tumor suppressors. Transforming growth factor-β receptor II (TGFβR2), as an important tumor suppressor, is involved ...

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV